323 related articles for article (PubMed ID: 27265756)
21. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
22. Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink.
Wilding J; Godec T; Khunti K; Pocock S; Fox R; Smeeth L; Clauson P; Fenici P; Hammar N; Medina J
BMC Med; 2018 Jul; 16(1):116. PubMed ID: 30008267
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
[TBL] [Abstract][Full Text] [Related]
24. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis.
Belsey J; Krishnarajah G
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():1-7. PubMed ID: 18435668
[TBL] [Abstract][Full Text] [Related]
25. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Amin NB; Aggarwal N; Pall D; Paragh G; Denney WS; Le V; Riggs M; Calle RA
Diabetes Obes Metab; 2015 Aug; 17(8):751-9. PubMed ID: 25885172
[TBL] [Abstract][Full Text] [Related]
26. Progression to treatment failure among Chinese patients with type 2 diabetes initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes Registry.
Jiang G; Luk AO; Yang X; Wang Y; Tam CHT; Lau SH; Ozaki R; Kong APS; Tong PC; Chow CC; Chan JCN; So WY; Ma RCW
Diabetes Res Clin Pract; 2016 Feb; 112():57-64. PubMed ID: 26703273
[TBL] [Abstract][Full Text] [Related]
27. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.
Schroner Z; Javorsky M; Tkacova R; Klimcakova L; Dobrikova M; Habalova V; Kozarova M; Zidzik J; Rudikova M; Tkac I
Diabetes Obes Metab; 2011 Jan; 13(1):89-91. PubMed ID: 21114608
[TBL] [Abstract][Full Text] [Related]
28. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Fonseca V; Gill J; Zhou R; Leahy J
Diabetes Obes Metab; 2011 Sep; 13(9):814-22. PubMed ID: 21481127
[TBL] [Abstract][Full Text] [Related]
29. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
30. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Matthews DR; Dejager S; Ahren B; Fonseca V; Ferrannini E; Couturier A; Foley JE; Zinman B
Diabetes Obes Metab; 2010 Sep; 12(9):780-9. PubMed ID: 20649630
[TBL] [Abstract][Full Text] [Related]
31. Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
Bruce DG; Davis WA; Davis TME
Diabetes Obes Metab; 2018 Dec; 20(12):2852-2859. PubMed ID: 30003670
[TBL] [Abstract][Full Text] [Related]
32. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Azar ST; Echtay A; Wan Bebakar WM; Al Araj S; Berrah A; Omar M; Mutha A; Tornøe K; Kaltoft MS; Shehadeh N
Diabetes Obes Metab; 2016 Oct; 18(10):1025-33. PubMed ID: 27376711
[TBL] [Abstract][Full Text] [Related]
34. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
35. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
Int J Clin Pract; 2013 Oct; 67(10):1005-14. PubMed ID: 23981060
[TBL] [Abstract][Full Text] [Related]
36. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
Desai U; Kirson NY; Kim J; Khunti K; King S; Trieschman E; Hellstern M; Hunt PR; Mukherjee J
Diabetes Care; 2018 Oct; 41(10):2096-2104. PubMed ID: 30131396
[TBL] [Abstract][Full Text] [Related]
37. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
[TBL] [Abstract][Full Text] [Related]
38. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
Bell DS; Dharmalingam M; Kumar S; Sawakhande RB
Diabetes Obes Metab; 2011 Sep; 13(9):800-5. PubMed ID: 21477065
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M; Frid A; Hermansen K; Thomsen AB; During M; Shah N; Tankova T; Mitha I; Matthews DR
Diabetes Obes Metab; 2013 Mar; 15(3):204-12. PubMed ID: 22985213
[TBL] [Abstract][Full Text] [Related]
40. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
